Sat.Sep 14, 2024 - Fri.Sep 20, 2024

article thumbnail

Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama

Fierce Pharma

With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential blockbuster in tow. | Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced Wednesday. The crown jewel of the deal is undoubtedly Vtama, Dermavant’s steroid-free cream for plaque psoriasis, which is looking at a major expansion opportunity in eczema.

322
322
article thumbnail

*EVENT* The Silent Edge: October 9 in NYC

Authentic Influence Group

The Silent Edge: How Body Language and Communication Skills Shape Leadership Success October 9, 2024 | 8:00 AM | NYC Free Event | Limited to 30 Seats Enjoy a Breakfast Bagel | Take in the NYC Skyline | Master Leadership Through Body Language Harness the power of what’s not being said. Join Shelly O’Donovan to master body language that transforms your leadership presence, influences decisions, and builds stronger teams.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Mass Board Exodus at 23andMe Leaves Company With Tough Decisions Ahead

MedCity News

Months after 23andMe CEO Anne Wojcicki publicly stated she wants to take the company she co-founded private, all of the company’s independent board directors have resigned. The board letter to Wojcicki stated that its members preferred resigning over continuing to have a difference of view over the direction of the company. The post Mass Board Exodus at 23andMe Leaves Company With Tough Decisions Ahead appeared first on MedCity News.

article thumbnail

Top three trends in precision medicine

Pharmaceutical Technology

An innovative approach to healthcare, precision medicine is a new medical model that takes into account individual differences in genes, environments, and lifestyles to drive better outcomes through medicine.

Medicine 105
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval

Fierce Pharma

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. With the nod, Dupixent becomes the first biologic treatment for COPD patients in the U.S.

FDA 311
article thumbnail

ESMO: Enhertu shows its worth in brain metastases

pharmaphorum

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona – showed that nearly two-thirds (61.6%) of patients with brain metastases at baseline who were treated with the HER2-directed antibody-drug conjugate (ADC) were alive without disease progression at one year.

Patients 106

More Trending

article thumbnail

After the Lykos debacle, what’s next for psychedelic therapies?

Pharmaceutical Technology

While Lykos Therapeutics’ MDMA therapy was rejected by the FDA, psychedelic therapy advocates remain optimistic about the sector.

FDA 119
article thumbnail

Bristol Myers Squibb axes 79 more in NJ as $1.5B cost-reduction program rolls on

Fierce Pharma

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program. | Bristol Myers Squibb is laying off an additional 79 staffers in Lawrenceville, New Jersey. The cuts will be effective between Dec. 12 and May 30 of next year and are part of BMS's $1.5 billion cost reduction program.

289
289
article thumbnail

PBM strikes back at FTC over drug pricing report

pharmaphorum

PBM Express Scripts has sued the FTC, claiming its recent report on the sector's role in drug pricing is defamatory and should be retracted

116
116
article thumbnail

The FDA Isn’t Blocking Medical Breakthroughs — Our Outdated Innovation Model Is

MedCity News

The current model of siloed, proprietary development is failing us. It’s slow, expensive, and often results in technologies that never see the light of day. What if, instead, we embraced an open-source approach to medical device innovation? The post The FDA Isn’t Blocking Medical Breakthroughs — Our Outdated Innovation Model Is appeared first on MedCity News.

Medical 123
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

AI boom set to revolutionise healthcare in Europe

Pharmaceutical Technology

The growth of AI in the healthcare sector is already having real-world impacts and promises a step-change in future care.

article thumbnail

GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales

Fierce Pharma

This summer, GSK cut its yearly vaccine sales projection o | In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.

Sales 292
article thumbnail

Astellas brings its first digital health product to US

pharmaphorum

Astellas is ready to launch its first digital health product in the US, called Digitiva, which provides at-home monitoring of people with heart failure

106
106
article thumbnail

What Will It Take to Improve Healthcare Cybersecurity?

MedCity News

During a panel discussion at MedCity News’ INVEST Digital Health conference, three healthcare leaders shared their expert insight on what needs to change in order to improve the industry’s cybersecurity strategy. The post What Will It Take to Improve Healthcare Cybersecurity? appeared first on MedCity News.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Enhancing Banking Sales Strategies For Future Growth

Integrity Solutions

Banking sales strategies are being redefined: Here’s how to pivot your customer relationships. While every industry grapples with the volatility of the economic environment and market conditions, banking and financial services organizations are dealing with specific challenges emerging from multiple disruptive forces: These challenges include: Maintaining an acceptable margin in a volatile yield curve market.

article thumbnail

New migraine drugs less effective than previous generation of triptan meds: BMJ study

Fierce Pharma

A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migra | A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migraines than a previous class of medicines.

Medicine 288
article thumbnail

ESMO: GSK, iTeos bring some optimism back to TIGIT

pharmaphorum

GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class

109
109
article thumbnail

Organon Gets More Skin in the Game by Acquiring Roivant’s Dermatology Subsidiary

MedCity News

By acquiring Dermavant, Organon gets Vtama, a drug approved for treating plaque psoriasis. An FDA decision for the topical cream in atopic dermatitis is expected by the end of 2024. The post Organon Gets More Skin in the Game by Acquiring Roivant’s Dermatology Subsidiary appeared first on MedCity News.

FDA 121
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

FDA expands Novartis’ Kisqali label to include early breast cancer patients

Pharmaceutical Technology

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData analysis.

Sales 98
article thumbnail

With FDA nod, AstraZeneca's FluMist becomes first self-administered flu vaccine

Fierce Pharma

AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on AstraZeneca's influenza vaccine FluMist for self-administration by adults up to 49 years old and for administration by a parent or caregiver in kids between the ages of 2 and 17. With the green light, FluMist is now the only flu vaccine in the U.S. patients can give to themselves.

FDA 272
article thumbnail

FDA clears sleep apnoea feature for new Apple Watch

pharmaphorum

Apple has the FDA authorisation it needs to bring its software for detecting sleep apnoea to the Apple Watch, coinciding with the launch of its new operating system for the wearable.The Breathing Disturbances function is part of watchOS 11, which makes its debut today alongside the release of the latest Apple Watch Series 10 which was revealed at the company's new product reveal earlier this month and is due to become available on 20th September.

FDA 94
article thumbnail

Millions are Taking a Drug that Falls Short of its Promise to Lower Risk of Heart Attack

MedCity News

While fibrates are proven to lower triglyceride levels, which can serve as a biomarker for cardiovascular disease risk, several major clinical studies from the past 20 years have failed to show a benefit of fenofibrates over and above statins in further reducing heart-related events. The post Millions are Taking a Drug that Falls Short of its Promise to Lower Risk of Heart Attack appeared first on MedCity News.

FDA 113
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech

Pharmaceutical Technology

Roche has secured approval from the US Food and Drug Administration for Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology.

article thumbnail

Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer

Fierce Pharma

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. | An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis' Kisqali and Eli Lilly's Verzenio in early breast cancer.

FDA 288
article thumbnail

Support app for young cancer patients launches in UK

pharmaphorum

Rates of cancer among people aged 24 and below are rising fast, but health systems are often not catering well enough to the specific needs of this age group.A new partnership has been set up between the Ella Dawson Foundation, a UK-based charity for young people with cancer, and digital cancer care company Careology to try to tackle that deficit and improve their treatment and wellbeing.

article thumbnail

New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds

MedCity News

Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020. The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News.

article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

GC Therapeutics secures $65m to launch into off-the-shelf iPSC therapy space 

Pharmaceutical Technology

The biotech has secured $65m in a Series A funding round led by Cormorant Asset Management and other investors.

article thumbnail

Granules India scolded over truckloads of torn manufacturing documents after recent FDA inspection

Fierce Pharma

From truckloads of torn documents to avian incursions in the production plant, Granules India’s recent manufacturing reprimand from the FDA is alarming no matter which way you look at it. | Earlier this month, Granules was slapped with a Form 483 following an inspection of its Telangana facility in India that ran from Aug. 26 to Sept. 6. The FDA’s report cites six observations around poor quality control procedures, subpar cleaning, cross-contamination risks and more.

article thumbnail

ESMO: Pfizer drug helps cancer patients gain weight

pharmaphorum

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia in a phase 2 trial presented at ESMO

Patients 100
article thumbnail

Medicare Reimbursement for Doctors is in Critical Condition

MedCity News

Doctor’s offices are the front door of the American healthcare system. We owe it to them to support H.R. 2474 and put an end to annual Congressional stop-gap spending bills. The post Medicare Reimbursement for Doctors is in Critical Condition appeared first on MedCity News.

Doctors 117
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time